000276936 001__ 276936
000276936 005__ 20240229155007.0
000276936 0247_ $$2doi$$a10.1002/ijc.34630
000276936 0247_ $$2pmid$$apmid:37337948
000276936 0247_ $$2ISSN$$a0020-7136
000276936 0247_ $$2ISSN$$a1097-0215
000276936 0247_ $$2altmetric$$aaltmetric:151705538
000276936 037__ $$aDKFZ-2023-01213
000276936 041__ $$aEnglish
000276936 082__ $$a610
000276936 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000276936 245__ $$aLongitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients.
000276936 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000276936 3367_ $$2DRIVER$$aarticle
000276936 3367_ $$2DataCite$$aOutput Types/Journal article
000276936 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690462418_31842
000276936 3367_ $$2BibTeX$$aARTICLE
000276936 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276936 3367_ $$00$$2EndNote$$aJournal Article
000276936 500__ $$a#EA:C110#LA:C110# / 2023 Sep 15;153(6):1192-1200
000276936 520__ $$aCancer-related fatigue is commonly treated in an undifferentiated manner, because its pathophysiology is still not well understood. Therefore, we investigated if bioelectrical phase angle (PhA), a non-invasive marker of cell integrity, could help to single out specific fatigue subtypes. In a randomized controlled strength training intervention trial, PhA was measured by bioelectrical impedance analysis in 158 breast cancer patients. Fatigue was assessed with the multidimensional 20-item Fatigue Assessment Questionnaire. Multiple regression analyses considering changes in PhA and fatigue from baseline to post-intervention and ANCOVA models investigating the strength training effect on PhA were conducted. Further, explorative mediation and moderation analyses were performed. Decrease (=worsening) in PhA was significantly associated with increase in physical (P = .010) and emotional (P = .019) fatigue. These associations were markedly stronger in patients with normal BMI (interaction P = .059 and .097) and with low pre-diagnosis exercise level (interaction P = .058 and .19). Among patients with normal BMI strength training was associated with an increase in PhA (ANCOVA P = .059), but not among overweight/obese patients (interaction P = .035). Chemotherapy was a major determinant for low PhA, but PhA did not mediate the effect of chemotherapy on fatigue. In conclusion, PhA has a significant inverse association with physical and emotional fatigue. This association is moderated by BMI and previous exercise. Significant relationships of PhA were also observed with chemotherapy and strength training. Thus, PhA might be a marker that could help in the classification of subtypes of fatigue with different pathophysiology, which may require specifically tailored treatment. Further research on this is warranted.
000276936 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276936 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276936 650_7 $$2Other$$abioimpedance analysis
000276936 650_7 $$2Other$$acancer-related fatigue
000276936 650_7 $$2Other$$aexercise
000276936 650_7 $$2Other$$aquality of life
000276936 650_7 $$2Other$$asurvivorship
000276936 7001_ $$aChong, Marvin$$b1
000276936 7001_ $$aKlassen, Oliver$$b2
000276936 7001_ $$aWiskemann, Joachim$$b3
000276936 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4$$eLast author$$udkfz
000276936 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34630$$gp. ijc.34630$$n6$$p1192-1200$$tInternational journal of cancer$$v153$$x0020-7136$$y2023
000276936 909CO $$ooai:inrepo02.dkfz.de:276936$$pVDB
000276936 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000276936 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000276936 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276936 9141_ $$y2023
000276936 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000276936 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000276936 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000276936 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000276936 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000276936 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000276936 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000276936 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000276936 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000276936 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000276936 980__ $$ajournal
000276936 980__ $$aVDB
000276936 980__ $$aI:(DE-He78)C110-20160331
000276936 980__ $$aUNRESTRICTED